BioNano Genomics logo
BioNano Genomics BNGO
$ 1.69 -1.74%

Quarterly report 2025-Q3
added 11-13-2025

report update icon

BioNano Genomics Financial Statements 2011-2025 | BNGO

Annual Financial Statements BioNano Genomics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

3.55 M 683 K 37 M 614 M 1.47 B 37.4 M 40.8 M - - - - - - -

Shares

1.27 M 569 K 28.9 M 277 M 133 M 34.3 M 10.1 M - - - - - - -

Historical Prices

2.79 1.2 1.28 2.22 11.1 1.03 4.1 - - - - - - -

Net Income

-112 M -232 M -133 M -72.4 M -41.1 M -29.8 M -18.5 M -23.4 M -18.8 M - - - - -

Revenue

30.8 M 36.1 M 27.8 M 18 M 8.5 M 10.1 M 12 M 9.51 M 6.79 M - - - - -

Cost of Revenue

30.4 M 26.6 M 21.9 M 14.1 M 5.73 M 6.77 M 8.71 M 6.03 M - - - - - -

Gross Profit

- - - - 2.77 M 3.36 M 3.29 M 3.47 M 3.21 M - - - - -

Operating Income

-104 M -215 M -132 M -77.1 M -38.6 M -25.9 M -20.4 M -23.2 M - - - - - -

Interest Expense

-10.1 M -20.5 M 298 K 927 K 2.52 M 2.29 M 1.38 M 591 K - - - - - -

EBITDA

-90 M -202 M -122 M -73.8 M -37.1 M -24.7 M -19.1 M -21.1 M -20.1 M - - - - -

Operating Expenses

- - - - 41.3 M 29.2 M 23.7 M 26.1 M 24.4 M - - - - -

General and Administrative Expenses

51.9 M 92.8 M 88.6 M 58.5 M 31.1 M 20.2 M 14.2 M 14.1 M 13 M - - - - -

All numbers in USD currency

Quarterly Income Statement BioNano Genomics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

5.34 M 3.44 M 2.69 M 1.87 M 1.43 M 1.13 M 879 K 45.8 M 35 M 31.5 M 30.2 M 29.7 M 29 M 28.6 M 285 M 290 M 280 M 279 M 264 M 190 M 133 M 90.9 M 35.6 M 34.3 M 10.9 M 10.9 M 10.2 M 10.1 M 7.78 M 3.36 M 3.32 M 77.3 K 2.92 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-8.5 M -6.86 M -3.1 M - -44.2 M -16.2 M -31.4 M - -113 M -38.9 M -37.1 M - -31.8 M -32.2 M -30 M - -20.8 M -18.8 M -9.95 M - -10.8 M -8.07 M -10.5 M -7.9 M -6.4 M -6.4 M -7.9 M -6.41 M -4.93 M -3.31 M -3.85 M 5.92 M -23.4 M 6.67 M 5.69 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

7.37 M 6.73 M 6.46 M - 6.07 M 7.77 M 8.77 M - 9.32 M 8.66 M 7.42 M - 7.22 M 6.67 M 5.7 M - 4.66 M 3.86 M 3.17 M - 2.2 M 1.18 M 1.14 M 2.79 M 3.31 M 2.18 M 1.85 M 4.01 M 2.83 M 3.39 M 1.77 M 2.85 M 2.74 M 2.2 M 1.72 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

4 M 3.26 M 3.52 M - 14.5 M 5.19 M 5.94 M - 6.57 M 6.35 M 5.34 M - 5.41 M 5.2 M 4.84 M - 3.5 M 2.42 M 2.12 M - 1.46 M 603 K 856 K 1.69 M 2.38 M 1.56 M 1.15 M 2.99 M 3.07 M 1.81 M 841 K 1.5 M 1.69 M 1.64 M 1.21 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-8.54 M -7.8 M -8.46 M - -43.9 M -17 M -31.1 M - -113 M -39.2 M -37.8 M - -32.1 M -32.1 M -29.9 M - -20.7 M -16.5 M -11.2 M - -10.2 M -7.44 M -9.76 M - -5.68 M -6.84 M -6.18 M - -5.97 M -4.01 M -4.34 M - -5.03 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-219 K 676 K 5.08 M - -697 K 363 K -1.36 M - -45 K -330 K 76 K - 73 K 74 K 77 K - 2 K 210 K 603 K - 589 K 561 K 761 K - 578 K 645 K 273 K - 404 K 408 K 302 K - 145 K - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -6.03 M - - - -28.1 M - - - -34.7 M - -25.3 M -32.1 M -27.7 M - -19.2 M -16.5 M -10.7 M - -9.32 M -6.84 M -9.47 M - -5.41 M -6.58 M -5.92 M - -5.58 M -3.63 M -3.94 M - -4.79 M - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

9.06 M 8.35 M 9.03 M - 9.46 M 11.6 M 19.1 M - 24.9 M 26.9 M 26 M - 21.2 M 21.8 M 20.3 M - 15.3 M 13.8 M 9.53 M - 8.66 M 5.61 M 7.37 M - 4.45 M 5.06 M 4.79 M - 3.22 M 3.49 M 2.9 M - 3.12 M - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements BioNano Genomics BNGO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting BioNano Genomics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
DexCom DexCom
DXCM
$ 64.79 2.0 % $ 25 B usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 17.23 1.5 % $ 99.4 M israelIsrael
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 21.15 11.37 % $ 233 M chinaChina
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 101.24 0.04 % $ 18.8 B usaUSA
Biomerica Biomerica
BMRA
$ 2.31 2.01 % $ 5.31 M usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Co-Diagnostics Co-Diagnostics
CODX
$ 0.36 -0.39 % $ 10.6 M usaUSA
Guardant Health Guardant Health
GH
$ 104.81 -0.39 % $ 12.9 B usaUSA
Celcuity Celcuity
CELC
$ 98.24 -0.25 % $ 3.88 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 11.75 -0.47 % $ 333 M israelIsrael
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 185.09 2.99 % $ 15.3 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 733.11 0.57 % $ 60.5 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 228.08 1.74 % $ 167 B usaUSA
Illumina Illumina
ILMN
$ 128.88 0.12 % $ 20.5 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 4.25 -3.41 % $ 136 K usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 267.33 -0.14 % $ 22.4 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 58.6 -0.81 % $ 4.06 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 589.45 0.25 % $ 18.2 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 457.09 -0.75 % $ 30.9 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
$ 7.06 -0.03 % $ 640 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 5.81 -1.43 % $ 3.12 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 12.02 -0.04 % $ 1.52 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 5.91 -0.25 % $ 1.28 B usaUSA
Biodesix Biodesix
BDSX
$ 7.79 - $ 1.01 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 16.27 -3.1 % $ 399 M usaUSA
Natera Natera
NTRA
$ 237.72 1.48 % $ 23.4 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 39.24 0.31 % $ 1.09 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 184.06 0.16 % $ 20.4 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 28.38 -0.49 % $ 858 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 2.33 4.69 % $ 591 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Precipio Precipio
PRPO
$ 24.56 8.81 % $ 31.9 M usaUSA
Personalis Personalis
PSNL
$ 10.09 4.18 % $ 598 M usaUSA
RadNet RadNet
RDNT
$ 79.11 -1.13 % $ 5.78 B usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina